MAPK8 and fibrosarcoma: The viability of ferroptosis inducer (erastin or RSL-3)-treated HT-1080 fibrosarcoma cell line–which was used in the description of ferroptosis [4]–could be further reduced by co-treatment with JNK inhibitors (JNK-IN-8 or SP600125) (Figure 1).